All In Biotech

Drug Trial Radar · NCT06421636

A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body

A PHASE 2, TWO-PART, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF SUBCUTANEOUSLY ADMINISTERED REGN7999 (AN INHIBITOR OF TMPRSS6) IN PARTICIPANTS WITH IRON OVERLOAD DUE TO NON-TRANSFUSION DEPENDENT β-THALASSEMIA

Last checked: Nov 19, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

19

Actual

Start

Sep 30, 2024

Primary completion

Dec 3, 2026

Study completion Dec 3, 2026

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
May 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called REGN7999 (called "study drug"). The study is focused on patients with non-transfusion dependent beta-thalassemia. The aim of the study is to see how safe and effective the study drug is. The study is looking at several other research questions, including: * Whether the study drug lowers extra iron levels in the body * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Conditions

  • Non-Transfusion Dependent Beta-Thalassemia (NTDT)

Interventions

  • REGN7999Drug

    Administered subcutaneous (SC)

  • PlaceboDrug

    Administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Liver Iron Concentration (LIC) by R2* Magnetic Resonance Imaging (MRI)Time frame: At week 24
  2. Incidence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to week 72
  3. Severity of TEAEsTime frame: Up to week 72

Locations

26 sites in 9 countries. Site status is shown where the registry gives one.

  • Weill Cornell Medicine

    New York, New York

  • K Eristavi National Center of Experimental and Clinical Surgery

    Tbilisi, Georgia

  • Medinvest Institute of Hematology and Transfusiology Limited

    Tbilisi, Georgia

  • University Hospital of Ioannina

    Ioannina, Greece

  • Children's Hospital Agia Sophia

    Athens, Attica, Greece

  • Laiko General Hospital of Athens

    Athens, Attica, Greece

  • Hemato-Oncology Clinic Ahmedabad PVT. LTD.

    Ahmedabad, Gujarat, India

  • Nirmal Hospital Pvt. Ltd - Surat

    Surat, Gujarat, India

  • Amrita Institute of Medical Sciences and Research Centre (AIMS)

    Kochi, Kerala, India

  • K J Somaiya Super Specialty Hospital & Research Centre

    Mumbai, Maharashtra, India

  • All India Institute of Medical Sciences, New Delhi

    New Delhi, National Capital Territory of Delhi, India

  • Indraprastha Apollo Hospitals

    New Delhi, National Capital Territory of Delhi, India

  • JK Lon Hospital

    Jaipur, Rajasthan, India

  • Day Hospital Thalassemia and Haemoglobinopathies (DHTE); A.O.U S.Anna

    Ferrara, Italy

  • Hospital Tunku Ampuan Besar Tuanku Aishah Rohani (HPKK UKM)

    Kuala Lumpur, Malaysia

  • Hospital Queen Elizabeth

    Kota Kinabalu, Sabah, Malaysia

  • Sarawak General Hospital

    Kuching, Sarawak, Malaysia

  • Hospital Ampang

    Ampang, Selangor, Malaysia

  • Chulalongkorn University

    Bangkok, Thailand

  • Phramongkutklao Hospital

    Bangkok, Thailand

  • Chiang Mai University

    Chiang Mai, Thailand

  • Srinagarind Hospital

    Khon Kaen, Thailand

  • Songklanagarind Hospital, Prince of Songkla University

    Hat Yai, Changwat Songkhla, Thailand

  • Hacettepe University

    Ankara, Turkey (Türkiye)

  • University College London Hospitals NHS Trust

    London, United Kingdom

  • Imperial College Healthcare NHS Trust

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.